Trial Profile

Phase I/II study on safety and efficacy of NMS-01940153E in adult patients with unresectable hepatocellular carcinoma (HCC) previously treated with systemic therapy

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 14 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs S 81694 (Primary)
Indications Carcinoma; Liver cancer
Focus Adverse reactions; Therapeutic Use
Sponsors Nerviano Medical Sciences

Most Recent Events

07 May 2025 Status changed from completed to discontinued.(Reason the study was stopped: In the Phase II part of the study, among the participants evaluable for efficacy, no objective (partial response or clinical response) was observed at the first futility analysis.)
27 Aug 2024 Status changed from active, no longer recruiting to completed.
26 Feb 2024 Planned End Date changed from 25 Mar 2026 to 27 Mar 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com